Compare Merck & Co., Inc. (MRK) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Prudential PLC — how do they compare? Merck & Co., Inc. trades at $142.17 (market cap $351.28B), while Prudential PLC trades at $24.03 (market cap $28.84B). The key difference: Merck & Co., Inc. is far larger — about 12.2× Prudential PLC's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Prudential PLC for 119 Days on average.
| MRK | PUK | |
|---|---|---|
Market Cap | $351.28B | $28.84B |
Volume | 7,969,665 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $156.43 | $33.61 |
52-Week Low | $82.49 | $23.54 |
Typical Hold Time | 98 Days | 119 Days |
Enterprise Value | $398.04B | $28.38B |
Dividend Yield | 2.39% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
PUK trades at $23.54, down 4.31% today, amid bearish technical signals. The company shows strong fundamentals with revenue growth from $16.2B in 2024 to $27.4B in 2025 and net income of $4.0B. Valuation ratios appear attractive with P/E of 8.28 and P/S of 1.01. Recent news highlights strategic shifts including emerging-market exits and a $3B capital rotation plan. Analyst consensus is moderately bullish with 50% buy ratings.
The outlook balances solid profitability and growth against technical weakness and macroeconomic risks. Investment appeal lies in undervalued metrics and strategic refocusing, but near-term price pressure and execution risks on new initiatives warrant caution. The stock offers value for long-term investors if the company delivers on its five-year strategic targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
